| Clinical data | |
|---|---|
| Trade names | Eminase |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 90 minutes |
| Identifiers | |
| CAS Number | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| Chemical and physical data | |
| Molar mass | approx. 131 kg/mol |
| (verify) | |
Anistreplase is a thrombolytic drug. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC). As a thrombolytic drug, it is used to treat blood clots in emergency situations.
Anistreplase is used to treat blood clots in emergency situations such as myocardial infarction.[1] Early treatment gives better outcomes.[1]
Anistreplase has been developed by Beecham under the brand name Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC) after its components.[1][2][3]
|
| |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antiplatelet drugs |
| ||||||||||||||
| Anticoagulants |
| ||||||||||||||
| Thrombolytic drugs/ fibrinolytics |
| ||||||||||||||
| Non-medicinal |
| ||||||||||||||
| |||||||||||||||
 | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
